摘要
目的对重症社区获得性肺炎ICU治疗采用血必净注射液的临床疗效进行观察、总结和分析。方法选取2013年12月至2015年12月浙江省肿瘤医院ICU接收的60例重症社区获得性肺炎患者为研究对象,随机分为观察组和对照组,每组各30例。其中对照组患者进行重症社区获得性肺炎的常规治疗,观察组患者在对照组治疗的基础上加用血必净注射液进行治疗。治疗结束后对两组患者的治疗效果进行对比。结果研究结果表明,观察组患者整体治疗效果明显优于对照组,主要体现在总有效率、危重患者综合评分、白细胞计数(WBC)、C-反应蛋白(CRP)以及降钙素原(PCT)等方面,两组比较差异显著,具有统计学意义(P<0.05)。结论重症社区获得性肺炎ICU治疗采用血必净注射液的总体临床效果较好,能够显著改善患者预后并提高患者的生命质量,适合在临床广泛应用。
Objective to observe, summarize and analyze the clinical efficacy of ICU treatment of Xuebijing injection to severe community acquired pneumonia. Methods Sixty cases of severe community acquired pneumonia patients admitted in ICU of our hospital from December 2013 to December 2015 were chosen as the research object, and were randomly divided into observation group and control group, with 30 cases in each group. The patients in control group received of conventional therapy, while the patients in observation group were treated with Xuebijing injection based on the therapy methods of control group. At end of the treatment, the efficacy of two groups were compared. Results After the treatment, the overall efficacy in observation group was better than that of control group, which was mainly reflected in the difference of total efficiency,comprehensive score of severe patients, white blood cell count(WBC), C-reactive protein(CRP) and calcitonin angiotensinogen(PCT) of the two groups, and the difference was statistically significant(P〈0.05). Conclusion Using Xuebijing injection for the ICU treatment of severe community acquired pneumonia have better clinical efficacy. It can significantly improve the prognosis of patients and improve the life quality of patients. So it is suitable for clinical application.
出处
《临床医学研究与实践》
2016年第15期39-40,共2页
Clinical Research and Practice